{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperthyroidism/prescribing-information/carbimazole/","result":{"pageContext":{"chapter":{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole","depth":2,"htmlHeader":"<!-- begin field 6984b481-ec35-4359-bad6-7b83da6fc764 --><h2>Carbimazole</h2><!-- end field 6984b481-ec35-4359-bad6-7b83da6fc764 -->","summary":"","htmlStringContent":"<!-- begin item 5bd853b7-93dd-48d4-97c7-cb61f3cb51cd --><!-- begin field e7a40c62-1c15-4f2b-aa75-a3c4cfbcffc8 --><ul><li>Carbimazole should only be initiated on specialist advice and should have ongoing specialist monitoring. The following is provided for reference purposes only.</li></ul><!-- end field e7a40c62-1c15-4f2b-aa75-a3c4cfbcffc8 --><!-- end item 5bd853b7-93dd-48d4-97c7-cb61f3cb51cd -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","lastRevised":"Last revised in January 2021","chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","fullItemName":"Management","slug":"management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"c2ebcee0-2d8f-54e2-ab23-7ffda9839e60","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0e8961d6-1c9c-4edf-877c-1871359e3261 --><h3>Contraindications and cautions</h3><!-- end field 0e8961d6-1c9c-4edf-877c-1871359e3261 -->","summary":"","htmlStringContent":"<!-- begin item 3a94bacb-f035-4ebb-9d2b-3c55d7ec4114 --><!-- begin field f8077d51-269a-44c5-802a-fa1a7b26b3c2 --><ul><li><strong>Carbimazole should not be prescribed to:</strong><ul><li>People with severe blood disorders.</li><li>People with severe hepatic impairment.</li><li>People with acute pancreatitis — carbimazole should be stopped immediately and permanently if acute pancreatitis occurs. Re-exposure to carbimazole may result in life-threatening acute pancreatitis.</li><li>Women of childbearing potential unless they are using effective contraception — carbimazole is associated with an increased risk of congenital malformations when used during the first trimester of pregnancy and at high doses. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for more information.</li></ul></li><li><strong>Carbimazole should be prescribed with caution to people with:</strong><ul><li>Mild to moderate hepatic impairment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">MHRA, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">MHRA, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field f8077d51-269a-44c5-802a-fa1a7b26b3c2 --><!-- end item 3a94bacb-f035-4ebb-9d2b-3c55d7ec4114 -->","subChapters":[]},{"id":"f99c9332-535b-5d26-9db6-bfa14f0d0c98","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 4e56bb32-72cf-40cb-ab06-8f1198b4c94e --><h3>Adverse effects</h3><!-- end field 4e56bb32-72cf-40cb-ab06-8f1198b4c94e -->","summary":"","htmlStringContent":"<!-- begin item 885ec0a0-78bc-49a1-9450-d6729cf143ac --><!-- begin field 0e530bc9-ce6f-4690-820d-875a53a3ca37 --><ul><li><strong>Adverse effects of carbimazole include:</strong><ul><li>Nausea, taste disturbance, headache, fever, malaise, arthralgia, skin reactions.</li><li>Bone marrow suppression (including pancytopenia, haemolytic anaemia, thrombocytopenia, and life-threatening agranulocytosis), myopathy, alopecia, and jaundice.</li><li>Acute pancreatitis — carbimazole should be stopped immediately and permanently if acute pancreatitis occurs. Re-exposure to carbimazole may result in life-threatening acute pancreatitis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">MHRA, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 0e530bc9-ce6f-4690-820d-875a53a3ca37 --><!-- end item 885ec0a0-78bc-49a1-9450-d6729cf143ac -->","subChapters":[]},{"id":"a721c20c-63e7-5e96-8772-57d6a822061d","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ac389f6a-dcad-4bd3-9f62-b9cdfc410e10 --><h3>Drug interactions</h3><!-- end field ac389f6a-dcad-4bd3-9f62-b9cdfc410e10 -->","summary":"","htmlStringContent":"<!-- begin item c1576bab-ac3d-47ae-a124-1e3cc7c4ef4b --><!-- begin field b4f4eae6-b3af-4769-8554-2c8523c2ef16 --><ul><li><strong>Possible drug interactions with carbimazole include:</strong><ul><li>Azathioprine — both carbimazole and azathioprine can increase the risk of myelosuppression.</li><li>Coumarins, such as warfarin — carbimazole possibly enhances the anticoagulant effect of coumarins. Additional monitoring of the international normalized ratio (INR) should be considered, and the dose of warfarin adjusted if needed.</li><li>Digoxin — carbimazole affects the concentration of digoxin. Manufacturer advises monitor and adjust dose.</li><li>Leflunomide — both carbimazole and leflunomide can increase the risk of myelosuppression.</li><li>Methotrexate — both carbimazole and methotrexate can increase the risk of myelosuppression.</li><li>Olanzapine — both carbimazole and olanzapine can increase the risk of myelosuppression.</li><li>Trimethoprim — both carbimazole and trimethoprim can increase the risk of myelosuppression.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Joint Formulary Committee, 2020</a>] </p><!-- end field b4f4eae6-b3af-4769-8554-2c8523c2ef16 --><!-- end item c1576bab-ac3d-47ae-a124-1e3cc7c4ef4b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}